Welcome to our dedicated page for Pfizer news (Ticker: PFE), a resource for investors and traders seeking the latest updates and insights on Pfizer stock.
Pfizer Inc. (PFE) is a global biopharmaceutical leader driving innovations in vaccine development and therapeutic treatments. This news hub provides investors and industry professionals with timely updates on corporate developments, regulatory milestones, and market strategies.
Access official press releases, earnings reports, and analysis of Pfizer's clinical trial progress. Our curated collection covers FDA approvals, partnership announcements, and research breakthroughs across oncology, immunology, and infectious disease portfolios.
Key updates include quarterly financial results, manufacturing expansions, and strategic collaborations shaping the pharmaceutical landscape. Bookmark this page for reliable insights into one of healthcare's most influential companies, with content organized for efficient navigation across devices.
Pfizer Inc. (NYSE: PFE) has announced a quarterly cash dividend of
AM Best has affirmed the Financial Strength Rating of A (Excellent) and the Long-Term Issuer Credit Rating of “a+” (Excellent) for
The company maintains substantial net property retentions and a diverse reinsurance program. Despite its low average loss ratios, it has moderate volatility in key metrics due to high retentions. Negative rating action could arise if Pfizer's support for Blue Whale diminishes.
Pfizer Inc. (NYSE: PFE) invites shareholders and the public to its virtual-only 2023 Annual Meeting of Shareholders on April 27, 2023, at 9:00 a.m. EDT. Shareholders can access the meeting via this link. Registration opens today, and shareholders may log in starting at 8:45 a.m. EDT. Questions can be submitted in advance until 5:00 p.m. EDT on April 25. Guests can join in listen-only mode. A replay will be available for up to one year at investors.pfizer.com.
FAQ
What is the current stock price of Pfizer (PFE)?
What is the market cap of Pfizer (PFE)?
